Jul 22, 2026 | Press Releases
Government acceptance initiates formal regulatory review of Entolimod under Ukraine’s Regulatory Equivalency pathway, with a potential review expected in as few as 45- to 60-days.Ukraine Ministry of Health Accepts Entolimod for Formal Review – Following...
Jul 20, 2026 | Press Releases
Sheba Medical Center, which is ranked the #7 hospital in the world, has chosen to evaluate and fund a trial of Valion Bio’s Entolimod in cancer patients, creating a second clinical development pathway beyond Acute Radiation Syndrome. Highlights Independent...
Jul 14, 2026 | Press Releases
Strategic execution across multiple initiatives positions the Entolimod platform to pursue opportunities in government preparedness, domestic biomanufacturing and oncology supportive careSAN ANTONIO, July 14, 2026 /PRNewswire/ — Valion Bio, Inc. (Nasdaq: VBIO)...
Jun 25, 2026 | Press Releases
AFRRI/NIAID partnership and validated animal models significantly derisk regulatory and commercial advancement of Company’s lead candidatePositive momentum further positions Entolimod as a potential first and only treatment for GI-ARS, representing a...
Jun 11, 2026 | Press Releases
Emanates from the FY27 NDAA process underway in the U.S. CongressPrioritizes radiation/nuclear countermeasures that are both prophylactic (radioprotectant) and therapeutic (radiomitigant) Follows Company’s two recent briefings for senior DoW officials regarding...
May 19, 2026 | Press Releases
Cross-Agency Discussion Highlights Interest in Oral Formulation as Field-Deployable Medical CountermeasureSAN ANTONIO, May 19, 2026 /PRNewswire/ — Valion Bio, Inc. (Nasdaq: VBIO), a late-stage innate immunotherapeutics company, today announced that it presented...